Shield Therapeutics plc (AIM: STX)

Market Cap	18.57M
Revenue (ttm)	16.99M
Net Income (ttm)	-28.62M
Shares Out	782.06M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,967,029
Average Volume	1,776,813
Open	2.445
Previous Close	2.425
Day's Range	2.325 - 2.500
52-Week Range	1.063 - 7.100
Beta	1.53
RSI	36.35
Earnings Date	Apr 25, 2025

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 73
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: STX

Financial Performance

In 2023, Shield Therapeutics's revenue was $13.09 million, an increase of 137.95% compared to the previous year's $5.50 million. Losses were -$33.29 million, -33.13% less than in 2022.

Financial numbers in USD